Vor Biopharma Inc.
Vor Biopharma Inc. is listed today as Vor Biopharma Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $110 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vor Biopharma Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2020).
SEC Form D · Jul 2020
The industry group it chose in its notices: Other.
SEC Form D · Jul 2020
That is all the official record says: Vor Biopharma Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Vor Biopharma Inc. are on record.
Investors#
10 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| 5AM Opportunities I (GP), LLC | Other | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| 5AM Opportunities I, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| 5AM Partners VI, LLC | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| 5AM Ventures VI, L.P. | Venture capital | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Alexandria Venture Investments, LLC | Venture capital | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| Nathan D. Jorgensen | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2021) | SEC Form 3 |
| PureTech Health LLC | Other | not stated | not stated | Held Series A-1, A-2 and B preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
| RA Capital Healthcare Fund LP | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Ra Capital Management, L.P. | Fund or asset manager | not stated | not stated | Held Series A-2 and B preferred stock, 10% owner, director (Form 3, 2021) | SEC Form 3 |
| Tirtha Chakraborty | Person | not stated | not stated | Held Series B preferred stock (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 33 investors.
Largest shareholders today
Institutions holding Vor Biopharma Inc. shares, as of Sep 30, 2026.
- FMR LLC$129 M11.00%
- TCG Crossover Management, LLC$108 M9.23%
- Ra Capital Management, L.P.$86 M7.33%
- Fcpm III Services B.V.$65 M5.54%
- BlackRock, Inc.$63 M5.38%
- Venrock Adviser, LLC$58 M4.95%
- Frazier Life Sciences Management, L.P.$52 M4.47%
- Vanguard Capital Management LLC$39 M3.31%
- State Street Corp$38 M3.21%
- Caligan Partners LP$37 M3.13%
- Great Point Partners LLC$22 M1.83%
- Millennium Management LLC$19 M1.61%
- Geode Capital Management, LLC$19 M1.59%
- Nantahala Capital Management, LLC$18 M1.52%
- Paradigm Biocapital Advisors LP$17 M1.45%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Amy Mendel | Executive officer | Jul 2020 |
| Nathan Jorgensen | Executive officer | Jul 2020 |
| Robert Ang | Executive officer | Jul 2020 |
| Joshua Resnick | Director | Jul 2020 |
| Kush Parmar | Director | Jul 2020 |
| Robert Ang | Director | Jul 2020 |
| Sven Lundberg | Director | Jul 2020 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.